Skip to content
  • Bioequivalence
  • Community
  • Investors

Now providing Mesenchymal cell-based immunomodulation for Covid19-induced hypercytokinemia. Call us to learn more

Somata
Genesis Biopharmaceuticals
  • Covid-19
    • Clinical Trials
    • Products
      • Ventilator
  • Treatments
    • Neurodegenerative Diseases
      • Multiple sclerosis
      • Amyotrophic lateral sclerosis
      • Parkinson’s disease
      • Cerebral palsy
      • Autism
    • Diabetes T2
    • Critical limb ischemia
    • Kidney disorder
    • Stroke
  • Biopharmaceuticals
    • Neutrojen
    • Somajen
    • Stem cells
  • Services
    • Bioequivalence
    • Pharmacokinetics
  • Discoveries
    • Multiple Sclerosis
    • COVID-19

Author: Mansi Dua

DermaLife K Keratinocyte Calcium-Free Medium Kit
Epithelial Media

DermaLife K Keratinocyte Calcium-Free Medium Kit

by Mansi Dua
- Nov. 08, 2017
chat_bubble_outline0
Read morearrow_forward
DermaLife K Keratinocyte Medium Complete Kit
Epithelial Media

DermaLife K Keratinocyte Medium Complete Kit

by Mansi Dua
- Nov. 08, 2017
chat_bubble_outline0
Read morearrow_forward
DermaLife K LifeFactors® Kit (for Keratinocytes)
Epithelial Media

DermaLife K LifeFactors® Kit (for Keratinocytes)

by Mansi Dua
- Nov. 08, 2017
chat_bubble_outline0
Read morearrow_forward
DermaLife Basal Medium — 500 mL
Epithelial Media

DermaLife Basal Medium — 500 mL

by Mansi Dua
- Nov. 08, 2017
chat_bubble_outline0
Read morearrow_forward
DermaLife Calcium-Free Basal Medium
Epithelial Media

DermaLife Calcium-Free Basal Medium

by Mansi Dua
- Nov. 08, 2017
chat_bubble_outline0
Read morearrow_forward

Posts navigation

Prev 1 2 3 4 … 22 Next
https://www.facebook.com/somatagenesis
PO Box 66 Albion ID 83311, USA
International +91 992 149 6595
USA +1 646 583 1660
info@somatagenesis.com
  • Neutrojen
  • Somajen
  • Stem cells
  • Bioequivalence
  • Contact
  • COVID-19
  • Multiple Sclerosis Research
Copyright © 2025 Somata Genesis, Inc. | 416, Burlington Tower, Business Bay, Dubai, United Arab Emirates
  • Facebook
  • LinkedIn
  • Twitter